Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair | NYU Langone Health

Go Back to All Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Colon Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1. Histologically proven stage III colon adenocarcinoma 2. DNA Mismatch Repair (MMR) Status: Presence of deficient (d) DNA mismatch repair (dMMR). 3. Tumors must have completely resected. 4. Entire tumor must be in the colon

You may not be eligible for this study if the following are true:

1. Tumor with rectal involvement 2. Prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for colon cancer except for one cycle of mFOLFOX6. 3. Patients with testing that did not show dMMR (loss of MMR protein)